PMID- 34799342
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220228
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 34
IP  - 4(Supplementary)
DP  - 2021 Jul
TI  - Spectroscopic interactions of non-insulin-dependent diabetes mellitus with 
      levocetirizine.
PG  - 1639-1644
AB  - Non insulin dependent diabetes mellitus (NIDDM) drugs such as glibenclamide and 
      metformin is employed to heterogeneous disorder characterized by alteration in 
      production of glucose due to impairment of both insulin secretion and insulin 
      action. These patients might suffer with allergic rhinitis and in this case, 
      there is a possibility to maintain patient on levocetirizine, an anti-allergic 
      drug commonly used in rhinitis. The object of the present study is to detect 
      possible interaction between glibenclamide or metformin with levocetirizine 
      Current study was performed using UV spectroscopic technique sing simultaneous 
      equation in pH simulated to gastric juice (pH 1), pH 4, pH 7.4 and in pH 9. All 
      drugs followed Beer Lambert's Law. Results showed that glibenclamide and 
      metformin can increase or decrease availability of levocetirizine and in the same 
      way levocetirizine can alter availabilities of glibenclamide and metformin in 
      different pH. Hence, drug interaction between glibenclamide or metformin with 
      levocetirizne occurred. This may be due to his may be due to the charge transfer 
      or binding capabilities of these drugs which resulted in significantly changed 
      availability of NIDDIM as well as levocetirizine. Therefore, co-administration of 
      these drugs should be avoided and furtherinvestigations at clinical and 
      pre-clinical levels should be done.
FAU - Mehboob, Shafaque
AU  - Mehboob S
AD  - Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, 
      Jinnah Sindh Medical University, Karachi, Pakistan.
FAU - Mehboob, Moona
AU  - Mehboob M
AD  - Department of Pharmaceutical Chemistry, School of Pharmacy, Dow University of 
      Health Science, Karachi, Pakistan.
FAU - Mehjabeen, -
AU  - Mehjabeen -
AD  - Department of Pharmacology, Faculty of Pharmaceutical Sciences, Federal Urdu 
      University of Arts, Science and Technology, Karachi, Pakistan.
FAU - Tariq Rafi, S M
AU  - Tariq Rafi SM
AD  - Department of ENT, Jinnah Sindh Medical University, Karachi, Pakistan.
FAU - Khan, Tariq
AU  - Khan T
AD  - Department of Pharmacology, Faculty of Pharmaceutical Sciences, Federal Urdu 
      University of Arts, Science and Technology, Karachi, Pakistan.
FAU - Anser, Humaira
AU  - Anser H
AD  - Department of Pharmacology, Institute of Pharmaceutical sciences, Jinnah Sindh 
      Medical University, Karachi, Pakistan.
FAU - Perveen, Shaheen
AU  - Perveen S
AD  - Department of Pharmaceutics, Institute of Pharmaceutical sciences, Jinnah Sindh 
      Medical University, Karachi, Pakistan.
FAU - Jahan, Noor
AU  - Jahan N
AD  - Department of Pharmacology, School of Pharmacy, Dow University of Health Science, 
      Karachi, Pakistan.
FAU - Wazir, Asma
AU  - Wazir A
AD  - Department of Pharmacognocy, Faculty of Pharmaceutical sciences, Jinnah 
      University for Women, Karachi, Pakistan.
FAU - Owais, Farah
AU  - Owais F
AD  - Department of Pharmacology, Faculty of Pharmaceutical Sciences, Federal Urdu 
      University of Arts, Science and Technology, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Solutions)
RN  - 6U5EA9RT2O (levocetirizine)
RN  - 9100L32L2N (Metformin)
RN  - SX6K58TVWC (Glyburide)
RN  - YO7261ME24 (Cetirizine)
SB  - IM
MH  - Cetirizine/chemistry/*pharmacokinetics
MH  - Drug Interactions
MH  - Glyburide/chemistry/*pharmacokinetics
MH  - Hypoglycemic Agents/*chemistry
MH  - Metformin/chemistry/*pharmacokinetics
MH  - Molecular Structure
MH  - Solutions
MH  - Spectrophotometry, Ultraviolet
EDAT- 2021/11/21 06:00
MHDA- 2022/03/01 06:00
CRDT- 2021/11/20 05:35
PHST- 2021/11/20 05:35 [entrez]
PHST- 2021/11/21 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2021 Jul;34(4(Supplementary)):1639-1644.